PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
PVCT was delisted on the 13th of October, 2016.
8 hedge funds and large institutions have $15K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
14% more funds holding
Funds holding: 7 → 8 (+1)
6% less capital invested
Capital invested by funds: $16K → $15K (-$999)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
Ancora Advisors
Cleveland,
Ohio
|
+$8 |
| 2 |
LIA
LBMC Investment Advisors
Brentwood,
Tennessee
|
+$1 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HFBOT
1
Home Federal Bank of Tennessee
Knoxville,
Tennessee
| $7K | – | – | – |
|
|
LDB
2
Lee, Danner & Bass
Nashville,
Tennessee
| $3K | – | – | – |
|
|
CCB
3
Cutter & Co Brokerage
Ballwin,
Missouri
| $2K | – | – | – |
|
|
ACM
4
Academy Capital Management
Waco,
Texas
| $1K | – | – | – |
|
5
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $1K | – | – | – |
|
|
AA
6
Ancora Advisors
Cleveland,
Ohio
| $1K | +$8 | +120 | +0.8% |
|
|
LIA
7
LBMC Investment Advisors
Brentwood,
Tennessee
| $1 | +$1 | +22,000 | New |
|
PVCT Hedge Fund Activity: Q3 2021 in Review
8 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q3 2021, worth a combined $15K — down 6.2% from $16K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new PVCT positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Ancora Advisors, adding an estimated $8.
- 8 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q3 2021, up from 7 in Q2 2021.
- Funds reported $15K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q3 2021, down 6.2% quarter-over-quarter.
- 1 fund opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q3 2021 and 0 closed out, a net change of +1 holder.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q3 2021 was Ancora Advisors, an estimated $8 added.
Based on aggregated 13F filings for Q3 2021.